Pharmafile Logo

TB Alliance

- PMLiVE

Novartis to acquire Excellergy in deal worth up to $2bn

Exl-111, a potential treatment included in the deal, is a central factor in many allergic diseases

- PMLiVE

Scotland becomes first part of UK to screen all newborn babies for SMA

The screening is part of a two-year evaluation funded by the Scottish government and Novartis

- PMLiVE

Novartis agrees on potential $3bn deal to buy Synnovations’s breast cancer treatment

The oral drug is currently being evaluated for breast cancer and other advanced solid tumours in a phase 1/2 study

- PMLiVE

Medscape Launches “Where Public Health Meets Practice” Learning Center to Translate Public Health Strategies into Patient Care

  The Medscape Division of Public Health announced the launch of the "Where Public Health Meets Practice" Learning Center, a dedicated educational destination on Medscape.org. The new center serves as...

Medscape Education

- PMLiVE

Novartis’ ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Approximately half of those with Sjögren’s disease are thought to be undiagnosed

- PMLiVE

Novartis agrees to lower drug prices in deal with US government

In 2025, the pharma company announced a $23bn US investment commitment

- PMLiVE

Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment

Around 9,000 people in the US currently live with SMA

- PMLiVE

Novartis announces plans for new US manufacturing hub

The US hub is expected to create 700 new jobs by 2030

- PMLiVE

Novartis reports primary endpoint reached in phase 3 malaria trial

The treatment demonstrated non-inferiority to current standard of care

- PMLiVE

Europe Celebrates the Heart of Healthcare Decision-Making as Laboratory Medicine Professionals Take Centre Stage

Today, the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) proudly marks European Laboratory Day, celebrating the professionals at the heart of healthcare decision making. Across Europe, laboratories will...

EatMoreFruit

- PMLiVE

Novartis presents new positive data for rheumatic autoimmune disease treatment

Patient outcome benefits were observed in two ongoing phase 3 trials

- PMLiVE

Novartis to acquire Avidity Biosciences in deal worth $12bn

The acquisition will expand Novartis’ neuroscience pipeline

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links